newsZeposia® (ozanimod) also demonstrated a low annualised relapse rate (ARR)…
14 October 2021 | By Anna Begley (European Pharmaceutical Review)
Zeposia® (ozanimod) also demonstrated a low annualised relapse rate (ARR) of 0.103 in the five-year Phase III DAYBREAK study.